Compare First Solar, Inc. (FSLR) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Natera Inc. Common Stock — how do they compare? First Solar, Inc. trades at $177.31 (market cap $20.05B), while Natera Inc. Common Stock trades at $394.16 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.8× First Solar, Inc.'s market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 76 Days and Natera Inc. Common Stock for 0 Days on average.
| FSLR | NTRA | |
|---|---|---|
Market Cap | $20.05B | $57.03B |
Volume | 2,420,017 | 1,131,157 |
Sector | Energy | Health |
52-Week High | $318.30 | $425.64 |
52-Week Low | $172.11 | $179.42 |
Typical Hold Time | 76 Days | 0 Days |
Enterprise Value | $18.52B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $179.08, down 0.36% with bearish technical signals despite strong fundamentals. The stock shows robust revenue growth from $2.6B in 2022 to $5.2B in 2025, with net income margins exceeding 29%. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 missed estimates. Analyst consensus remains positive with a $268.82 price target, while technical indicators show resistance near $181 with oversold RSI conditions.
FSLR presents a value opportunity with attractive valuation multiples (P/E 11.5, P/S 3.73) and strong profitability (ROE 18.51%). Risks include sector-wide pressure from high borrowing costs, patent litigation uncertainties, and recent insider selling. The stock's 35% decline from peaks creates potential upside if solar sector sentiment improves.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
